Barclays PLC Buys 68,688 Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Barclays PLC increased its position in shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) by 132.7% during the 3rd quarter, HoldingsChannel reports. The fund owned 120,464 shares of the company’s stock after purchasing an additional 68,688 shares during the quarter. Barclays PLC’s holdings in Poseida Therapeutics were worth $345,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in PSTX. Bank of New York Mellon Corp lifted its position in Poseida Therapeutics by 13.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 228,700 shares of the company’s stock valued at $668,000 after purchasing an additional 26,316 shares during the period. Principal Financial Group Inc. bought a new position in shares of Poseida Therapeutics during the second quarter worth $35,000. Rothschild Investment LLC acquired a new position in shares of Poseida Therapeutics in the 2nd quarter valued at $35,000. Rhumbline Advisers increased its position in shares of Poseida Therapeutics by 4.2% in the 2nd quarter. Rhumbline Advisers now owns 97,012 shares of the company’s stock valued at $283,000 after buying an additional 3,875 shares in the last quarter. Finally, Acadian Asset Management LLC raised its stake in Poseida Therapeutics by 9.4% during the 2nd quarter. Acadian Asset Management LLC now owns 399,839 shares of the company’s stock worth $1,165,000 after buying an additional 34,321 shares during the period. Institutional investors own 46.87% of the company’s stock.

Poseida Therapeutics Price Performance

NASDAQ PSTX opened at $9.52 on Friday. Poseida Therapeutics, Inc. has a 12-month low of $1.87 and a 12-month high of $9.65. The firm’s 50 day moving average is $6.66 and its 200-day moving average is $4.24. The company has a market capitalization of $930.81 million, a PE ratio of -15.11 and a beta of 1.64. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.68.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on PSTX shares. Cantor Fitzgerald lowered Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 26th. William Blair reaffirmed a “market perform” rating on shares of Poseida Therapeutics in a research note on Tuesday, November 26th. Piper Sandler downgraded shares of Poseida Therapeutics from an “overweight” rating to a “neutral” rating and set a $10.00 price objective for the company. in a research report on Monday, December 2nd. HC Wainwright reaffirmed a “neutral” rating and issued a $9.00 price objective (down from $20.00) on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. Finally, BTIG Research reiterated a “neutral” rating on shares of Poseida Therapeutics in a report on Tuesday, November 26th. Five research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $9.50.

Insider Buying and Selling at Poseida Therapeutics

In other Poseida Therapeutics news, Chairman Mark J. Gergen sold 30,000 shares of the company’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $9.46, for a total transaction of $283,800.00. Following the sale, the chairman now directly owns 651,291 shares of the company’s stock, valued at approximately $6,161,212.86. This represents a 4.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 2.90% of the company’s stock.

Poseida Therapeutics Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.